公开(公告)号：US20200155566A1

公开(公告)日：2020-05-21

申请号：US16632954

申请日：2018-08-01

Applicant: Novartis AG

Inventor： Susan Moody ,  Iain Mulford ,  Jordi Barretina

IPC: A61K31/55 ,  A61P35/00 ,  A61K31/519

Abstract: This invention relates to a pharmaceutical combination comprising (a) a third generation EGFR tyrosine kinase inhibitor and (b) a cyclin D kinase 4/6 (CDK4/6) inhibitor, particularly for use in the treatment of a cancer, particularly a lung cancer. This invention also relates to uses of such a combination for the preparation of a medicament for the treatment of a cancer; methods of treating a cancer in a subject in need thereof comprising administering to said subject a jointly therapeutically effective amount of said combination; pharmaceutical compositions comprising such combination and commercial packages thereto.

公开(公告)号：US11406633B2

公开(公告)日：2022-08-09

申请号：US16482836

申请日：2018-02-12

Applicant: Novartis AG

Inventor： Jason Russell Dobson ,  Susan Moody ,  Margaret Elise McLaughlin

IPC: A61K31/497 ,  A61P35/00 ,  A61K9/00 ,  C07K16/28

Abstract: The present disclosure relates to the field of pharmacy, particularly to a Wnt inhibitor and a PD-1 inhibitor for use in the treatment of cancer. Specifically, the disclosure relates to a pharmaceutical combination comprising a Wnt inhibitor, or a pharmaceutically acceptable salt thereof, and a PD-1 inhibitor, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer, to a method for the treatment of cancer that involves administering the combination and to the use of the combination for the manufacture of a medicament for the treatment of cancer.

公开(公告)号：US20200237773A1

公开(公告)日：2020-07-30

申请号：US16634924

申请日：2018-08-01

Applicant: Novartis AG

Inventor： Susan Moody ,  Lilli Petruzzelli ,  Jeffrey Engelman

IPC: A61K31/55 ,  A61K31/5377 ,  A61P35/00

Abstract: This invention relates to a pharmaceutical combination comprising (a) a third generation EGFR tyrosine kinase inhibitor and (b) a Raf inhibitor, particularly for use in the treatment of a cancer, particularly a lung cancer. This invention also relates to uses of such a combination for the preparation of a medicament for the treatment of a cancer; methods of treating a cancer in a subject in need thereof comprising administering to said subject a jointly therapeutically effective amount of said combination; pharmaceutical compositions comprising such combination and commercial packages thereto.

公开(公告)号：US20230063366A1

公开(公告)日：2023-03-02

申请号：US17809623

申请日：2022-06-29

Applicant: NOVARTIS AG

Inventor： Jason Russell Dobson ,  Susan Moody ,  Margaret Elise McLaughlin

IPC: A61K31/497 ,  A61P35/00 ,  A61K9/00 ,  C07K16/28

Abstract: The present disclosure relates to the field of pharmacy, particularly to a Wnt inhibitor and a PD-1 inhibitor for use in the treatment of cancer. Specifically, the disclosure relates to a pharmaceutical combination comprising a Wnt inhibitor, or a pharmaceutically acceptable salt thereof, and a PD-1 inhibitor, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer, to a method for the treatment of cancer that involves administering the combination and to the use of the combination for the manufacture of a medicament for the treatment of cancer.